search
Back to results

Autologous Bone Marrow Mononuclear Cells Therapy in Diabetic Lower Limb Ischemia

Primary Purpose

Diabetes, Lower Limb Ischemia

Status
Unknown status
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
autologous bone marrow mononuclear cells
Sponsored by
Hebei Medical University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes

Eligibility Criteria

20 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. fontaine's stage 2-4 or resting ABI <0.7
  2. age between 20 and 80 years old
  3. sign informed consent, voluntary subjects
  4. diagnosis of diabetic lower limb ischemia

Exclusion Criteria:

  1. poorly controlled diabetes (HBA1c> 7.0%) and proliferative retinopathy (III-IV stage)
  2. malignancy history in the past five years or serum level of tumor markers elevated more than doubled
  3. severe heart, liver, kidney, respiratory failure or poor general condition can not tolerate bone marrow mononuclear cells transplantation
  4. serious infections (such as cellulitis, osteomyelitis, etc.)
  5. pregnant female, or reproductive age female who wants to give birth throughout the course of the study
  6. life expectancy less than half a year

Sites / Locations

  • the First Hospital of Hebei Medical UniversityRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

autologous bone marrow mononuclear cells

Arm Description

Bone marrow come from the patients himself/herself. With a conventional method and reagent,Ficoll, mononuclear cells were isolated with deleting erythrocyte by density gradient centrifugation.

Outcomes

Primary Outcome Measures

Cell transplantation related side effect
Temperature,pulse,respiration,blood pressure,routine analysis of blood and urine, liver function,renal function,function of coagulation, ECG,cell transplantation related death and cell transplantation related unexpected amputation

Secondary Outcome Measures

ulcer size
Measuring ulcer area (cm2) and depth (mm)of limb : For each ulcer , photographically record the area and depth with a ruler in order to calculate the ulcer area in square millimeters.
rest pain score
Scoring the rest pain based on the degree of pain as following five scales): 0 level-0 point: no pain; level-1 point: occasional pain which can be recalled; level-2 points: the pain often but can be tolerated, without or with a little analgesics; level-3 points: often with need of general analgesics; level -4 points: affect sleeping due to the pain, general pain medication being difficult to alleviate. Before transplantation: points; after transplantation: points.
cold sensation score
based on a sense of cold as following five scales: 0 level-0 point: no cold sensation; level-1 point, or : Occasionally cold feeling; level-2 points: Often with cold feeling; level-3 points: significantly cold feeling. and can be significantly improved when using a local insulation. level-4 points: significantly cold feeling,and can not be significantly improved when using a local insulation.
Resting ABI
Measurement of ABI(ankle brachial index, ABI): Measure arterial pressure with a laser Doppler, and then calculate the ankle-brachial index, that is a ratio of ankle arterial blood pressure to brachial arterial blood pressure at rest.
Resting TcPO2 (mmHg)
Transcutaneous oxygen pressure(TcPO2) should be measured at the same site in the ischemic limb at rest.
Collateral vessel score
Collateral vessel score: Using computed tomographic angiography to score the collateral vessel formation. A mean score is obtained for each ischemic limb by 3 independent interventionists based on the following 4 level score: 0 (no new collateral vessels) (A little new collateral vessels) (moderate new collateral blood vessels) (Rich new collateral vessels)
Skin microcirculation measurement
using PeriMed "laser-Doppler flowmetry" measure the skin microcirculation on the same site in the ischemic limb at rest.

Full Information

First Posted
September 4, 2013
Last Updated
December 3, 2013
Sponsor
Hebei Medical University
search

1. Study Identification

Unique Protocol Identification Number
NCT01937416
Brief Title
Autologous Bone Marrow Mononuclear Cells Therapy in Diabetic Lower Limb Ischemia
Official Title
Safety and Efficacy Investigation of Patients With Diabetic Lower Limb Ischemia by Transplantation of Autologous Bone Marrow Mononuclear Cells
Study Type
Interventional

2. Study Status

Record Verification Date
December 2013
Overall Recruitment Status
Unknown status
Study Start Date
January 2012 (undefined)
Primary Completion Date
September 2013 (Actual)
Study Completion Date
December 2014 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hebei Medical University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study is to evaluate the safety and efficacy of autologous bone marrow mononuclear cells transplantation in diabetic patients with lower limb ischemia.
Detailed Description
Diabetic lower limb ischemia as severe complication of diabetes influences the life quality of patients and currently the effective treatment for the disease is lacking. Bone marrow mononuclear cells have been proved to have multiple functions including the differentiation and proliferation. In animal model, bone marrow mononuclear cells could induce angiogenesis and may have therapeutic usage for ischemia disease. The investigators thereby design the study to investigate the possible therapy of diabetic lower limb ischemia with autologous bone marrow mononuclear cells. Patient with diabetic lower limb ischemia was treated with colony stimulating factor for improvement of bone marrow hematopoiesis. Then bone marrow was taken and mononuclear cells were isolated with deleting erythrocyte by density gradient centrifugation. Bone marrow mononuclear cells were transplanted into ischemia regions of lower limb through intramuscular injection. The investigators investigated the safety of the therapy with life signs like temperature, pulse, blood pressure, routine analysis of blood and urine etc. post the transplantation. And the efficacy was evaluated with the measurement of ulcer size, rest pain score, cold sensation score, resting ABI, resting TcPO2, collateral vessel score and skin microcirculation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes, Lower Limb Ischemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
autologous bone marrow mononuclear cells
Arm Type
Experimental
Arm Description
Bone marrow come from the patients himself/herself. With a conventional method and reagent,Ficoll, mononuclear cells were isolated with deleting erythrocyte by density gradient centrifugation.
Intervention Type
Biological
Intervention Name(s)
autologous bone marrow mononuclear cells
Intervention Description
Bone marrow was taken from patient oneself and mononuclear cells were isolated with deleting erythrocyte by density gradient centrifugation. Bone marrow mononuclear cells were transplanted into ischemia regions of lower limb through intramuscular injection.
Primary Outcome Measure Information:
Title
Cell transplantation related side effect
Description
Temperature,pulse,respiration,blood pressure,routine analysis of blood and urine, liver function,renal function,function of coagulation, ECG,cell transplantation related death and cell transplantation related unexpected amputation
Time Frame
2 week after cell transplantation
Secondary Outcome Measure Information:
Title
ulcer size
Description
Measuring ulcer area (cm2) and depth (mm)of limb : For each ulcer , photographically record the area and depth with a ruler in order to calculate the ulcer area in square millimeters.
Time Frame
Post cell transplantation: 1, 3, 6 months
Title
rest pain score
Description
Scoring the rest pain based on the degree of pain as following five scales): 0 level-0 point: no pain; level-1 point: occasional pain which can be recalled; level-2 points: the pain often but can be tolerated, without or with a little analgesics; level-3 points: often with need of general analgesics; level -4 points: affect sleeping due to the pain, general pain medication being difficult to alleviate. Before transplantation: points; after transplantation: points.
Time Frame
Post cell transplantation: 1,3, 6 months
Title
cold sensation score
Description
based on a sense of cold as following five scales: 0 level-0 point: no cold sensation; level-1 point, or : Occasionally cold feeling; level-2 points: Often with cold feeling; level-3 points: significantly cold feeling. and can be significantly improved when using a local insulation. level-4 points: significantly cold feeling,and can not be significantly improved when using a local insulation.
Time Frame
Post cell transplantation: 1,3, 6 months
Title
Resting ABI
Description
Measurement of ABI(ankle brachial index, ABI): Measure arterial pressure with a laser Doppler, and then calculate the ankle-brachial index, that is a ratio of ankle arterial blood pressure to brachial arterial blood pressure at rest.
Time Frame
Post cell transplantation: 1,3, 6 months
Title
Resting TcPO2 (mmHg)
Description
Transcutaneous oxygen pressure(TcPO2) should be measured at the same site in the ischemic limb at rest.
Time Frame
Post cell transplantation:1, 3, 6 months
Title
Collateral vessel score
Description
Collateral vessel score: Using computed tomographic angiography to score the collateral vessel formation. A mean score is obtained for each ischemic limb by 3 independent interventionists based on the following 4 level score: 0 (no new collateral vessels) (A little new collateral vessels) (moderate new collateral blood vessels) (Rich new collateral vessels)
Time Frame
Post cell transplantation: 1,3, 6 months
Title
Skin microcirculation measurement
Description
using PeriMed "laser-Doppler flowmetry" measure the skin microcirculation on the same site in the ischemic limb at rest.
Time Frame
1,3,6 months post cell transplantation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: fontaine's stage 2-4 or resting ABI <0.7 age between 20 and 80 years old sign informed consent, voluntary subjects diagnosis of diabetic lower limb ischemia Exclusion Criteria: poorly controlled diabetes (HBA1c> 7.0%) and proliferative retinopathy (III-IV stage) malignancy history in the past five years or serum level of tumor markers elevated more than doubled severe heart, liver, kidney, respiratory failure or poor general condition can not tolerate bone marrow mononuclear cells transplantation serious infections (such as cellulitis, osteomyelitis, etc.) pregnant female, or reproductive age female who wants to give birth throughout the course of the study life expectancy less than half a year
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Baoyong Yan, Doctor
Organizational Affiliation
The First Hospital of Hebei Medical University
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Huimin Zhou, doctor
Organizational Affiliation
The First Hospital of Hebei Medical University
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Xu Han, master
Organizational Affiliation
The First Hospital of Hebei Medical University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Quanhai Li, doctor
Organizational Affiliation
The First Hospital of Hebei Medical University
Official's Role
Principal Investigator
Facility Information:
Facility Name
the First Hospital of Hebei Medical University
City
Shijiazhuang
State/Province
Hebei
ZIP/Postal Code
050000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xu Han, master
Phone
86-311-85917202
Email
hanxu98@126.com

12. IPD Sharing Statement

Learn more about this trial

Autologous Bone Marrow Mononuclear Cells Therapy in Diabetic Lower Limb Ischemia

We'll reach out to this number within 24 hrs